New Flow Imaging Nanoparticle Analyzer Enables Biopharmaceutical Manufacturers to Assess Colloidal Stability of Drug Formulations

Scarborough, ME, USA — The new FlowCam® Nano from global laboratory instrumentation manufacturer Fluid Imaging Technologies, Scarborough, Maine (www.FluidImaging.com), enables biopharmaceutical scientists to assess the colloidal stability of drug formulations to determine their resistance to aggregation over time. Ideal for testing therapeutic protein formulations, lyophilized biologics, and all injectable drugs, the FlowCam Nano is the first imaging flow microscope that automatically detects, images, and characterizes both micron- and submicron-sized particles in a fluid sample from 300 nm to 10 µm at the same time, allowing the aggregation or degradation of protein particles and additives to be tracked from manufacturing, storage, and transport through drug delivery. By understanding how the colloidal stability of different formulations compare, manufacturers are better able to balance efficacy, safety, and shelf life to find the ideal formulation that remains stable throughout the process.

To be unveiled at Pittcon 2018 booth #1628 on Feb. 26th in Orlando, Fla., and featured in a technical poster presentation at the conference, the FlowCam Nano enabled professor John F. Carpenter and Cheng Her, University of Colorado Denver - Anschutz Medical Campus to document differences in particle size distributions in different parenteral drug product formulations. By providing high resolutions images for opaque, transparent, and translucent sub-visible particles and corresponding measurement data using more than 40 different basic and advanced, morphological parameters, the FlowCam Nano led the researchers to conclude the new instrumentation effectively assesses the colloidal stability of drug product formulations.

For more information, contact Fluid Imaging Technologies, Inc.; 200 Enterprise Drive, Scarborough, Maine 04074; 207.289.3200.; Fax 207.289.3101; www.fluidimaging.com.